Finger Michael H.
CIK: 0001898925
Finger Michael H.'s purchase track record
How the stock did after each of Finger Michael H.'s open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since May 20, 2022
Stock higher 6 months later
33%
3 months: 33%
Median 6-month return
-40.0%
3 months: -28.2%
Beat the S&P 500
0%
median -47.6% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/27/2022 | CELZ | $1K | -28.2% | +2.5% | +8.9% |
| 6/14/2022 | CELZ | $7K | +2.1% | -40.0% | +7.6% |
| 5/20/2022 | CELZ | $10K | -28.9% | -60.8% | +1.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CELZ | ▼ Sell | Open Market | 750 | $4K | 2/19/2025 | View on chart |
| CELZ | ▼ Sell | Open Market | 750 | $4K | 2/18/2025 | View on chart |
| CELZ | ▲ Buy | Open Market | 2,000 | $1K | 9/27/2022 | View on chart |
| CELZ | ▲ Buy | Open Market | 10,000 | $7K | 6/14/2022 | View on chart |
| CELZ | ▲ Buy | Open Market | 6,500 | $10K | 5/20/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
CELZ raises BioDefense stake to 80% with $200K cash and share purchase
Creative Medical Technology announced it has purchased an additional 4 million BioDefense shares for $200,000 in cash and 1 million of its own shares. The transaction raises Creative’s ownership of BioDefense to about 80 percent. The increased stake may broaden Creative’s product portfolio and could influence future earnings.
CELZ raises BioDefense stake to 80% with $200K cash and share purchase. Creative Medical Technology announced it has purchased an additional 4 million BioDefense shares for $200,000 in cash and 1 million of its own shares. The transaction raises Creative’s ownership of BioDefense to about 80 percent. The increased stake may broaden Creative’s product portfolio and could influence future earnings.